Hawaiian Holdings Inc (HA): Holy shit. HAHAHAH That just made me...

eastunder · 2023-12-03T20:37:58.5300000Z

Holy shit. HAHAHAH That just made me a ton of money. LOL What a hoot! That can't be real.

Play Episode

7min

Proactive - Interviews for investors

Clinical study SKNJCT-003 shows positive trends as company advances skin cancer research in UAE

Medicus Pharma CEO Dr. Raza Bokhari joined Steve Darling from Proactive to share updates on the ongoing SKNJCT-003 clinical study, which is being conducted at nine sites across the United States and aims to randomize 60 patients. An interim analysis conducted after enrolling more than half of the targeted participants has shown encouraging results. The study reports a clinical clearance rate exceeding 60%, with the investigational therapy demonstrating strong tolerability across both tested dosage levels. Notably, no dose-limiting toxicities (DLTs) or serious adverse events (SAEs) have been observed, and there have been no systemic effects or clinically significant abnormalities in laboratory results, ECGs, vital signs, or physical exams. These promising findings will be submitted to the U.S. Food and Drug Administration (FDA) as part of a Type C meeting request in Q2 2025. In parallel, the company is advancing its clinical initiatives for non-invasive basal cell carcinoma treatment with a newly proposed study. This randomized, double-blind, placebo-controlled, multi-center trial has been submitted for approval to the UAE Department of Health. The study aims to enroll up to 36 patients at prominent medical institutions, including Cleveland Clinic Abu Dhabi, Sheikh Shakbout Medical City, Burjeel Medical City, and the American Hospital of Dubai. Participants will be assigned in a 1:1:1 ratio to receive either a placebo or one of two dosage levels of the experimental treatment. This expansion into the UAE represents a significant step forward in the company’s mission to develop innovative, non-invasive therapies for skin cancer, broadening its global clinical footprint and reinforcing its commitment to advancing patient care. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch

Proactive - Interviews for investors

NSX CEO highlights mining focus & direct listings as key growth drivers for 2025

National Stock Exchange of Australia CEO Max Cunningham talked with Proactive's Angela Harmantas from the PDAC conference in Toronto about the exchange’s role in the Australian market, its focus on mining companies, and its expansion plans. Cunningham explained that the NSX is one of two active stock exchanges in Australia with a tier-one license, allowing it to serve all investors, including retail. He highlighted that around one-third of the exchange’s listings are mining-related, with strong growth potential in the sector. Cunningham noted that NSX is working to fill a gap in the Australian venture market and is focusing on attracting mining companies, especially from regions like Perth. He also emphasized the importance of international relationships, mentioning cross-listing agreements with Canadian exchanges such as the CSE and TSX, as well as OTC Markets. Looking ahead to 2025, Cunningham discussed the challenges of IPOs due to regulatory hurdles and capital-raising difficulties. Instead, the NSX is prioritizing direct listings, which allow companies to go public without raising capital upfront. He stated that NSX is seeing increased interest from firms moving from the incumbent Australian exchange, as well as from Canadian companies seeking dual listings. #NSX #StockMarket #MiningStocks #IPOs #DirectListings #PDAC2025 #Investing #AustralianMarkets #DualListings #CapitalMarkets

Proactive - Interviews for investors

Lisata Therapeutics expands drug discovery with GATC AI collaboration

Lisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo talked with Proactive about the company’s strategic collaboration with GATC Health, a leader in artificial intelligence-driven drug discovery. Mazzo explained that GATC’s technology, which is recognized by Lloyd’s of London for clinical trial risk assessment, will be used to analyze Lisata’s lead candidate, certepetide, and identify potential new drug combinations. Mazzo highlighted that this collaboration will optimize Lisata’s ongoing cancer research, including trials in pancreatic ductal adenocarcinoma, cholangiocarcinoma, and other cancers. He noted that GATC’s AI technology can perform billions of simulations rapidly, potentially reducing the cost and risk of drug development. Discussing Lisata’s 2025 outlook, Mazzo described it as a "data-rich year," with upcoming results from the ASCEND trial and other studies. He emphasized the potential for certepetide in combination with immunotherapy and the company’s ongoing discussions with regulatory agencies and potential partners. To watch more interviews like this, visit Proactive’s YouTube channel. Don't forget to like this video, subscribe, and enable notifications for future updates. #LisataTherapeutics #Biotech #CancerResearch #AIinHealthcare #DrugDevelopment #ClinicalTrials #GATCHealth #Pharma #Oncology #Investing

Proactive - Interviews for investors

Millennial Potash advances Banio Project with resource potential and government support

Millennial Potash Corp (TSX-V:MLP, OTCQB:MLPNF) is advancing its Banio Potash Project in Gabon, leveraging extensive historical data and significant resource potential. Speaking at the PDAC conference in Toronto, Chairman Farhad Abasov shared key updates with Proactive’s Angela Harmantas, highlighting the project’s economic viability, strategic location, and government support. A recently completed economic assessment confirmed a 1.7 billion tonne indicated and inferred resource estimate, reinforcing the project’s scale and cost competitiveness. Abasov emphasized Banio’s proximity to major agricultural markets such as Brazil, India, China, and Africa, ensuring strong demand for its potash production. Gabon’s mining reforms have strengthened the project’s outlook, with the government actively supporting the Banio Project. Abasov noted a recent visit from the country’s president, signaling confidence in its economic and strategic value. Key milestones for 2024 include ongoing environmental studies, a second phase of drilling to expand the resource base, and the initiation of a feasibility study, which will run parallel to environmental assessments and is expected to conclude by early 2025. With strong backing, a large resource base, and a clear path to development, Millennial Potash is positioning itself as a major future supplier of potash, supporting global food security while contributing to Gabon’s economic growth. #tsxv #mlp #otcqb #mlpnf MillennialPotash #PotashMining #GabonMining #BanioProject #MiningInvestment #NaturalResources #MiningStocks #Commodities #SustainableMining #ProactiveInvestors

Followers	198
Posts	48228
Boards Moderated	1
Alias Born	11/09/2004

Volume:	-
Day Range:
Bid:	18.00
Ask:	17.99
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

HA Detailed Quote

Recent HA News

More HA News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent HA News

Go Ad-Free